Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04569773 | Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer | active not recruiting | — | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05364008 | FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea(FRIEND) | active not recruiting | Phase 3 | 33 | Yale UniversityOTHER | 1 | Aug 20, 2026 |
| clinicaltrials |
| NCT07777094 | TS Triage of HR-HPV Positive Population and Its Accuracy Study | active not recruiting | — | 300 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06402383 | Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living With HIV | active not recruiting | N/A | 2,000 | Dr. Karen YeatesOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06943833 | A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)(IVOLGA) | active not recruiting | Phase 2 | 37 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05415709 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | active not recruiting | Early Phase 1 | 35 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT00514254 | Risk Factors for Endometrial Cancer in Black Women | active not recruiting | — | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05722288 | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers | active not recruiting | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05063916 | Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04269200 | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer(DUO-E) | active not recruiting | Phase 3 | 805 | AstraZenecaINDUSTRY | 22 | Aug 7, 2026 | clinicaltrials |
| NCT05673252 | CERvical Cancer The InFlammatory Index (CERTIFIKO)(CERTIFIKO) | active not recruiting | — | 128 | University of Campania Luigi VanvitelliOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07038369 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | active not recruiting | Phase 1 | 134 | Atavistik Bio, IncINDUSTRY | 4 | Aug 7, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | active not recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT07746024 | Advancing Risk Stratification in Endometrial Cancer(DaPHNE) | active not recruiting | — | 400 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02595879 | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | active not recruiting | Phase 3 | 813 | National Cancer Institute (NCI)NIH | 5 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03526432 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | active not recruiting | Phase 2 | 110 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05047913 | Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR | active not recruiting | Early Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06715241 | A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS(COLIBRI-2) | active not recruiting | Phase 2 | 77 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)(ASCENT-GYN-01) | active not recruiting | Phase 3 | 640 | Gilead SciencesINDUSTRY | 19 | Jul 29, 2026 | clinicaltrials |
| NCT07735039 | Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV)(DUAL-HPV) | active not recruiting | N/A | 76 | Dr. Lutfi Kirdar Kartal Training and Research HospitalOTHER_GOV | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02912572 | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | active not recruiting | Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05538897 | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | active not recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06182241 | Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2 | active not recruiting | N/A | 80 | Boston University Charles River CampusOTHER | 2 | Jul 27, 2026 | clinicaltrials |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | active not recruiting | Phase 2 | 120 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT03120624 | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer | active not recruiting | Phase 1 | 34 | Mayo ClinicOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04092270 | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06746116 | A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain(DUoENDE) | active not recruiting | Phase 3 | 45 | AstraZenecaINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04622670 | Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer | active not recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06533059 | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | active not recruiting | Phase 1 | 110 | Alterome Therapeutics, Inc.INDUSTRY | 8 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06611540 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06611553 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2026 | clinicaltrials |
| NCT04214067 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | active not recruiting | Phase 3 | 164 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07681414 | ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy | active not recruiting | — | 52 | Guizhou Provincial People's HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07202936 | Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe | active not recruiting | — | 168 | University of BernOTHER | 1 | Jun 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials